Grand Ballroom I and II

8:00 am Coffee Room Networking

8:50 am Chair’s Opening Remarks

9:00 am Industry Leaders Fireside Chat

Synopsis

  • An executive panel discussion from leaders in the allogeneic cell therapy field
  • Understand their thoughts about autologous vs allogeneic, and the future of the cell therapy field
  • Ask your questions to understand expert’s thoughts on key topics including gene engineering, moving into the clinic, CMC, super donors and more

10:00 am The Patient Experience: Solid Tumor Cell Therapies in the Context of Standard Care

  • Brian Van Tine Professor, Medicine & Pediatrics, Washington University School of Medicine in St. Louis

Synopsis

  • Review how allogeneic cell therapies impact patients in comparison to approved treatments
  • Evaluate methods to measure clinical benefit such as survival and quality of life
  • Understand the importance of considering more than a cost-benefit analysis

10:30 am Industrializing Allogeneic-Based Cell & Gene Therapies

  • Marcos Langtry Head of Commercial Development Allogeneic Cell Therapy, Lonza

Synopsis

  • A standardized, systematic approach to commercialization
  • Challenges and solutions for cGMP manufacturing
  • Current and future technologies

11:00 am Morning Refreshment Break

3:00 pm Afternoon Refreshment Break & Networking

3:30 pm Allogeneic Genome-Engineered HSCT Enabling Post-Transplant Targeted Therapies

Synopsis

  • Concept of creating treatment-resistant stem cell transplants via gene deletion of cell surface targets
  • Implementing next-generation allogeneic healthy donor material supply chain to GMP engineered HSC transplants
  • Coupling genome-engineered HSCT with CAR-T and beyond

4:00 pm A Full Landscape Overview of the Allogeneic Cell Therapy Space

Synopsis

  • Assessing how allogeneic cell therapies align with the rest of the cell therapy landscape
  • What does the existing allogeneic landscape consist of and how has it changed over recent years
  • Insights into potential trends and the potential future of allogeneic therapies for oncology

4:30 pm Closing Remarks & Close of Conference